# Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

> **NCT00861692** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 20 (actual)

## Conditions studied

- Heparin-induced Thrombocytopenia Type II

## Interventions

- **DRUG:** argatroban

## Key facts

- **NCT ID:** NCT00861692
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861692, "Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00861692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*